Literature DB >> 24902569

False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results.

T H Boyles1, J Hughes2, V Cox2, R Burton3, G Meintjes4, M Mendelson1.   

Abstract

Xpert(®) MTB/RIF is the initial diagnostic test of choice for tuberculosis (TB). It is not known if false-positive results are more common in previously treated patients. We report four patients with successful treatment for TB up to 5 years previously who presented with respiratory tract infection and were Xpert-positive, but had negative TB cultures and clinical improvement without anti-tuberculosis treatment. We hypothesise that the Xpert results were false-positive due to the presence of dead Mycobacterium tuberculosis bacilli in lungs and sputum. Further work is required to determine the specificity of Xpert in previously treated patients.

Entities:  

Mesh:

Year:  2014        PMID: 24902569     DOI: 10.5588/ijtld.13.0853

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  27 in total

1.  Rapid Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert Assay: A Clinical Study.

Authors:  Deepak Arora; Neerja Jindal; Renu Bansal; Shilpa Arora
Journal:  J Clin Diagn Res       Date:  2015-05-01

2.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

3.  Xpert MTB/RIF false detection of rifampin-resistant tuberculosis from prior infection.

Authors:  J Daniel Kelly; Shou-Yean Grace Lin; Pennan M Barry; Chris Keh; Julie Higashi; John Z Metcalfe
Journal:  Am J Respir Crit Care Med       Date:  2014-12-01       Impact factor: 21.405

4.  Retrospective Analysis of False-Positive and Disputed Rifampin Resistance Xpert MTB/RIF Assay Results in Clinical Samples from a Referral Hospital in Hunan, China.

Authors:  Peilei Hu; Hongtai Zhang; Joy Fleming; Guofeng Zhu; Shuai Zhang; Yaguo Wang; Fengping Liu; Songlin Yi; Zhongnan Chen; Zhenhua Chen; Binbin Liu; Daofang Gong; Li Wan; Xingyun Wang; Yunhong Tan; Liqiong Bai; Lijun Bi
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 5.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 6.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

7.  Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients.

Authors:  John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Reggie Mutetwa; Renée A Peñaloza; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

Review 8.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

9.  Diagnostic Accuracy of the Small Membrane Filtration Method for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Prevalence Setting.

Authors:  Yap Boum; Soyeon Kim; Patrick Orikiriza; Carlos Acuña-Villaorduña; Solange Vinhas; Maryline Bonnet; Dan Nyehangane; Juliet Mwanga-Amumpaire; Kevin P Fennelly; Edward C Jones-López
Journal:  J Clin Microbiol       Date:  2016-03-30       Impact factor: 5.948

10.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.